Comment on

• Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia.

  Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Maor Y, et al. J Infect Dis. 2009 Mar 1;199(5):619-24. doi: 10.1086/596629. J Infect Dis. 2009. PMID: 19199552
• Accessory gene regulator dysfunction: an advantage for Staphylococcus aureus in health-care settings?

  Sakoulas G, Moise PA, Rybak MJ. Sakoulas G, et al. J Infect Dis. 2009 May 15;199(10):1558-9. doi: 10.1086/598607. J Infect Dis. 2009. PMID: 19392634 No abstract available.
• Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet?

  Holland TL, Fowler VG Jr. Holland TL, et al. J Infect Dis. 2011 Aug 1;204(3):329-31. doi: 10.1093/infdis/jir275. J Infect Dis. 2011. PMID: 21742827 No abstract available.
• Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations.

  Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan MV, Anderson TL, Roberts SA, Gao W, Christiansen KJ, Coombs GW, Johnson PD, Howden BP. Holmes NE, et al. J Infect Dis. 2011 Aug 1;204(3):340-7. doi: 10.1093/infdis/jir270. J Infect Dis. 2011. PMID: 21742831